TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05869955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-97540
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Specified dose on specified days
Study: NCT06323291

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Coaching Sessions
Description: Enrolled participants will set up an account through a secure and encrypted web portal managed by Osara Health.~Coaches will follow-up with their designated patients and/or caregivers to schedule individual coaching sessions via phone, text, or email depending on the participant's communication preference. Participants will have an initial coaching consultation by phone to go over the purpose and structure of coaching sessions.~Participants will then have an additional 3-4 coaching sessions (depending on time availability and need) to discuss symptom management, nutrition and exercise, sleep, and mindfulness.~Participants will receive content for each of the modules via email.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Coaching Sessions
Description: Enrolled participants will set up an account through a secure and encrypted web portal managed by Osara Health.~Coaches will follow-up with their designated patients and/or caregivers to schedule individual coaching sessions via phone, text, or email depending on the participant's communication preference. Participants will have an initial coaching consultation by phone to go over the purpose and structure of coaching sessions.~Participants will then have an additional 3-4 coaching sessions (depending on time availability and need) to discuss symptom management, nutrition and exercise, sleep, and mindfulness.~Participants will receive content for each of the modules via email.
Study: NCT06215118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: cereblon-modulating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: cereblon-modulating agent
Study: NCT06205238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGA
Description: CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGA
Description: CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up.
Study: NCT06380517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminopia
Description: dichoptic movies/shows shown through a virtual reality headset

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye
Study: NCT05571059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Sodium
Description: Once daily oral ifetroban

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo
Study: NCT05971303

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires will be given to patients, interpreters and cancer car professionals with aims of delineating the attitudes and experiences of patients, interpreters and cancer care professionals involved in the care of oncology patients with gynecologic malignancies

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires will be given to patients, interpreters and cancer car professionals with aims of delineating the attitudes and experiences of patients, interpreters and cancer care professionals involved in the care of oncology patients with gynecologic malignancies

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires will be given to patients, interpreters and cancer car professionals with aims of delineating the attitudes and experiences of patients, interpreters and cancer care professionals involved in the care of oncology patients with gynecologic malignancies
Study: NCT06780254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH-001
Description: capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules
Study: NCT06788444

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: The colonoscopy
Description: Both groups continued to receive the usual standard of gastroenterology care throughout the study period. The patients undergo preoperative preparation according to the requirements of colonoscopy. After entering the endoscopy room, the routine monitoring including electrocardiogram, heart rate, noninvasive blood pressure (BP), respiratory rate, and oxygen saturation (SpO2) are applied for patients. All monitoring data including HR, BP and SpO2 will be recorded at intervals of 3min. Safety assessments will be performed throughout the the research process. As a risk mitigation measure, esketamine should not be administered in patients with systolic blood pressure (SBP) \> 140 mmHg or diastolic blood pressure (DBP) \>90 mmHg prior to administration.~After the right upper limb venous access is opened, the patients is placed in the left lateral position. The oxygen mask is placed near the patients' nose and oxygen is provided by the mask for 6L/min during the colonoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The colonoscopy
Description: Both groups continued to receive the usual standard of gastroenterology care throughout the study period. The patients undergo preoperative preparation according to the requirements of colonoscopy. After entering the endoscopy room, the routine monitoring including electrocardiogram, heart rate, noninvasive blood pressure (BP), respiratory rate, and oxygen saturation (SpO2) are applied for patients. All monitoring data including HR, BP and SpO2 will be recorded at intervals of 3min. Safety assessments will be performed throughout the the research process. As a risk mitigation measure, esketamine should not be administered in patients with systolic blood pressure (SBP) \> 140 mmHg or diastolic blood pressure (DBP) \>90 mmHg prior to administration.~After the right upper limb venous access is opened, the patients is placed in the left lateral position. The oxygen mask is placed near the patients' nose and oxygen is provided by the mask for 6L/min during the colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The propofol is administered until the patients loss of consciousness (loss of the eyelash refex). The 0.2 mg/kg esketamine is then administered by the anesthesiologist, but should be discontinued if the SBP ≥200 mmHg or the DBP ≥110 mmHg. After the administration of the 0.2 mg/kg esketamine is completed, the endoscopist will begin the colonoscopic procedure.
Study: NCT06552793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autogenous partially demineralized dentin graft
Description: tooth cleaning : form decay, tartar, soft tissue debris, fillings, cement then cut into fragments (5×5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). A disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.The decontamination of the granules will take place through UVA rays and ultrasounds, with temperature variations always lower than 43 ◦C to avoid damage to proteins. After 25 min, particle graft biomaterials will be obtained. The particles size will range from 815 µm with peaks up to 1110 µm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft
Description: Cortico-cancallous Bovine powder
Study: NCT04646746

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% wheat
Description: 100 g of bread backed with 100% wheat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50% nude barley and 50% wheat
Description: 100 g of bread backed with 50% nude barley and 50% wheat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 75% nude barley and 25% wheat
Description: 100 g of bread backed with 75% of nude barley and 25% wheat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50% gene-modified high-amylose barley and 50% wheat
Description: 100 g of bread backed with 50% gene-modified high-amylose barley and 50% wheat
Study: NCT04748328

Intervention type: PROCEDURE
Intervention: ACL Reconstruction surgery and Rehabilitation Treatment
Description: ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise

Intervention type: PROCEDURE
Intervention: ACL Reconstruction surgery and Rehabilitation Treatment
Description: ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
Study: NCT05504187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: KP104 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: KP104 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: KP104 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: KP104 will be administered.
Study: NCT06412835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cooperative learning
Description: Students working in groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cooperative learning
Description: Students working in groups
Study: NCT06788860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tri-directional Ultrasound-guided Needle Knife Release
Description: This procedure involves ultrasound-guided tri-directional needle knife release for the treatment of trigger finger. Local anesthesia using 3-5 ml of 1% lidocaine and 0.25% bupivacaine will be administered for patient comfort. It aims to ensure precise tissue dissection while minimizing risks and improving outcomes.~Device: Sonosite M-Turbo Ultrasound Machine with Linear Probe HFL38x (6-13 MHz) is used for real-time imaging during the procedure.
Study: NCT06789666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARTCan App
Description: The ARTCan App is an art therapy technology application program. The application can be accessed via the web (via computer, phone, or on a device such as an iPad). With the use of the application, participants complete weekly sessions that culminate in an art piece. Note that participants are not required to have expertise in drawing; developing art skills or assessing the quality of art pieces is not the focus of the ARTCan program.~Subjects will upload a photo of the art they created to this application to show proof of completion of art therapy. They will also answer questions specific to the art therapy theme for the week.
Study: NCT06276023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful and Self-Compassionate Care Program (MASC)
Description: The intervention arm will be comprised of:~Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program (HEP)
Description: The control arm will be comprised of:~Six Virtual Group Sessions. The sessions will discuss caregiver stress, sleep hygiene, nutrition, and ways to stay physically active as a caregiver.~At Home Practice. After each group session, participants will have the opportunity to complete journal exercises that encourage them to integrate the health information that they learn into their daily lives.
Study: NCT05142358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Use of CPAP device at the start of treatment planning.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Use of CPAP device at the start of treatment planning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep inspiratory breath hold
Description: Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep inspiratory breath hold
Description: Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Breath
Description: Regular breathing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Breath
Description: Regular breathing
Study: NCT05408949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EPTL
Description: In EPTL it involves eccentric training in Full range (with dumbbells 15-10 RM) of Internal and external rotation at scapular plane elevation (0-45) degree and Flexion, Abduction, in full range (5 repetitions with a 45 second hold at slow speed) to target the series elastic component of the muscle .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HSR
Description: In HSR it involves eccentric training in mid-range of motion (with dumbbells 15-10 RM) targeting the contractile component of the muscles and improving mechanical strength. Additionally, when there is 90% pain reduction on NPRS functional rehabilitation program start and they follow the same program as Group A.
Study: NCT05506085

Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation of Globus Pallidus interna
Study: NCT04688450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIGORIS Blood Pressure Management Clinical Decision Support System
Description: Software system to optimize tight blood pressure management during vasopressor infusion
Study: NCT06790017

Intervention type: OTHER
Intervention: body temperature
Description: Body temperature measurement will be performed in the preoperative and intraoperative periods.

Intervention type: OTHER
Intervention: body temperature
Description: Body temperature measurement will be performed in the preoperative and intraoperative periods.
Study: NCT06787742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: full pulpotomy
Description: access to dental pulp chamber under aseptic condition, collect blood sample using a micropipette for ELIZA test, stop bleeding using sodium hypochlorite 2.5%, pulpotomy dressing material over pulp stump and final restoration with resign modified glass ionomer and composite resign

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: full pulpotomy
Description: access to dental pulp chamber under aseptic condition, collect blood sample using a micropipette for ELIZA test, stop bleeding using sodium hypochlorite 2.5%, pulpotomy dressing material over pulp stump and final restoration with resign modified glass ionomer and composite resign
Study: NCT06789432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and ezetimibe 10 mg
Description: Atorvastatin/Ezetimibe 10/10mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Description: Atorvastatin (20 mg) Monotherapy once daily
Study: NCT06792461

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity and nutritional behavioural intervention
Description: Digital eHealth platform to improve physical activity levels and dietary habits
Study: NCT06789705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: MDMA will be administered in a single dose of 50 mg (2 capsules of 25 mg MDMA) or 25mg (1 capsule of 25 mg MDMA, 1 capsule containing only mannitol filler) and given at treatment visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: MDMA will be administered in a single dose of 50 mg (2 capsules of 25 mg MDMA) or 25mg (1 capsule of 25 mg MDMA, 1 capsule containing only mannitol filler) and given at treatment visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be prepared as identical gelatin capsules containing only mannitol filler and given at treatment visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be prepared as identical gelatin capsules containing only mannitol filler and given at treatment visit.
Study: NCT06789198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccination of Fusion-VAC-XS15
Description: FusionVAC-22 peptide will be administered subcutaneously (s.c.) with the TLR1/2 ligand XS15 (50 µg) emulsified in Montanide ISA 51 VG (1:1).~A total of two vaccinations are planned, 4 weeks apart from each other. If no sufficient T cell response is achieved at the end of treatment visit (28 days after last vaccination) a booster vaccination at day 56 (+7 days) after the second vaccination can be applied
Study: NCT04815161

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adherence
Description: Adherence to medication using an electronic pillbox
Study: NCT06229353

Intervention type: BIOLOGICAL
Intervention: Gardasil 9
Description: Prevent HPV-associated diseases and cancers
Study: NCT05908513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar chemical structure of NAC but without function
Study: NCT04872738

Intervention type: OTHER
Intervention: Survey
Description: Patients in all groups will complete surveys about their decision to receive or not to receive the COVID-19 vaccine. For those who did receive the vaccine, they will indicate their experience with the vaccination and any side effects they may have experienced.

Intervention type: OTHER
Intervention: Survey
Description: Patients in all groups will complete surveys about their decision to receive or not to receive the COVID-19 vaccine. For those who did receive the vaccine, they will indicate their experience with the vaccination and any side effects they may have experienced.
Study: NCT04453020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS of the LHA
Description: Deep Brain Stimulation of the Lateral Hypothalamic Area
Study: NCT06056102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: * Safety Run-in: 375mg/m\^2 daily x 3~* Cohort 1: 375mg/m\^2 daily x 3~* Cohort 2: 375mg/m\^2 daily x 3~* Cohort 3: 375mg/m\^2 daily x 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-BCMA
Description: * Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19
Description: * Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: • Cohort 3: 24mg/m\^2 daily x 3
Study: NCT06549946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixovex-1
Description: Ixovex-1 is a novel oncolytic human adenovirus serotype 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixovex-1
Description: Ixovex-1 is a novel oncolytic human adenovirus serotype 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixovex-1
Description: Ixovex-1 is a novel oncolytic human adenovirus serotype 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanised antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanised antibody
Study: NCT06226571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNDX-5613
Description: Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Regimen
Description: Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HiDAC
Description: Consolidation: Participants will receive HiDAC IV.
Study: NCT04880863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAP (Naptumomab estafenatox)
Description: Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4. NAP will be administered in a dose of 10 μg/kg/day by IV bolus on Days 1 - 4 of treatment cycles 1-6. Starting cycle 7, NAP at a higher dose of 15 μg/kg will be administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is administered in combination with the study drug, NAP, on Day 5 of the treatment cycles 1-6. Starting cycle 7, Docetaxel will be administered in combination with the study drug, NAP, on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is administered as pre-medication on Day -13 and -12 of the first treatment cycle.
Study: NCT06000956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jitongning tablets
Description: The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a simulated agent of Jitongning tablets
Description: The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.
Study: NCT05928390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide Diaspartate
Description: Injectable ampoules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide Diaspartate
Description: Injectable ampoules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide Diaspartate
Description: Injectable ampoules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pasireotide Diaspartate
Description: Injectable ampoules